WideCells Group PLC Result of AGM (1192T)

TIDMWDC

RNS Number : 1192T

WideCells Group PLC

29 June 2018

29 June 2018

WideCells Group PLC ('WideCells Group' or 'the Group')

Result of Annual General Meeting

WideCells Group PLC, the healthcare services company focused on providing stem cell services and ground-breaking insurance for stem cell treatment, is pleased to announce that all resolutions put to the meeting were duly passed at the Group's Annual General Meeting held earlier today. Resolutions 9 and 10 were not put to the meeting, as equivalent resolutions had been duly passed at the Group's General Meeting held on 28 June 2018.

**ENDS**

For further information, please visit the Group's website www.widecellsgroup.com, follow us on Twitter @WideCells_Group or contact:

 
 WideCells Group      CEO - João Andrade    Tel: +351 919 
  PLC                                             033 171 
-------------------  -------------------------  -------------- 
 Smaller Company      Broker - Jeremy Woodgate   Tel: +44 (0) 
  Capital Limited      & Rupert Williams          20 3651 2912 
-------------------  -------------------------  -------------- 
 Shard Capital        Broker - Damon Heath       Tel: +44 (0) 
  Partners LLP         & Erik Woolgar             20 7186 9950 
-------------------  -------------------------  -------------- 
 St Brides Partners   PR - Charlotte Page        Tel: +44 (0) 
  Limited              & Isabel de Salis          20 7236 1177 
-------------------  -------------------------  -------------- 
 

Notes to Editors

WideCells Group PLC

WideCells Group PLC is building an integrated stem cell services company, focused on making stem cell treatments accessible and affordable. This is achieved through three divisions:

The Group has three divisions:

-- CellPlan: the world's first stem cell healthcare insurance plan with financial cover for medical treatment, travel and accommodation expenses and concierge service to manage the treatment process.

-- WideCells: The Institute of Stem Cell Technology has been established and is based in the University of Manchester Innovation Centre to provide stem cell storage services and focus on stem cell research and regenerative medicine. Its international cryogenics division specialises in stem cell storage, with the Group currently offering umbilical cord blood and tissue storage services to clients in the UK and Europe under the brand name BabyCells.

-- Wideacademy: an education and training division to promote awareness of the benefits of stem cell storage across the global general practice community.

The Group has built an experienced senior management team that has been integral to the development of its growth and business to date.

Stem Cell Fast Facts:

-- Cord blood (which is taken from the umbilical cord) provides the most effective source of stem cells for families due to it being simple, safe and painless to collect relative to other sources of stem cells such as bone marrow - WideCells will focus on promoting the collection and storage of cord blood.

-- Since 2005, there has been a 300% increase in the number of illnesses that can be treated using stem cells.

   --     82 illnesses can currently be treated using stem cell procedures. 

-- Despite initial storage often costing no more than a few GBPthousand, actual treatment can cost in the GBPhundreds of thousands

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 (MAR). On publication of this announcement, this inside information is now considered to be in the public domain.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

RAGFKCDPNBKDQAB

(END) Dow Jones Newswires

June 29, 2018 10:00 ET (14:00 GMT)